Nobivac®: Respira Bb
The UK's FIRST and ONLY injectable canine Bordetella vaccineLearn more
INNOVATION ENABLING FLEXIBILITY
Nobivac® Respira Bb brings further innovation and flexibility to your canine infectious respiratory disease (CIRD) vaccination offering, empowering you to select the optimal approach for your patients, ensuring that all dogs who would benefit from protection can receive it.Learn more
Protection Against Canine Infectious Respiratory Disease (CIRD)
CIRD is a common infectious disease of ‘social dogs’, with a wide range of pathogens implicated. Bordetella bronchiseptica is an important pathogen within this complex syndrome, but many pet dogs in the UK are currently unprotected against Bordetella bronchiseptica, whilst being regularly vaccinated against the core diseases.Learn more
Bordetella bronchiseptica and Canine parainfluenza vaccination
Nobivac® Respira Bb1
|Fimbrial antigen (unique subunit) of Bordetella bronchiseptica
|7 months (if missed, booster can be administered within 12 months of primary vaccination)
|Once a year
|10 dose multi-dose vial
|Once a year (when Nobivac DHPPi is not administered)
|10 and 50 dose packs
|Canine parainfluenza and Bordetella bronchiseptica
|Once a year
|5 and 25 dose packs
- Nobivac® Respira Bb. Summary of Product Characteristics.
- Nobivac® Pi. Summary of Product Characteristics.
- Nobivac® KC. Summary of Product Characteristics.
Nobivac® Pi is a live attenuated vaccine containing canine parainfluenza virus. POM-V
Nobivac® Respira Bb is an inactivated subunit vaccine containing the fimbrial antigen of Bordetella bronchiseptica. POM-V
Nobivac® KC is an intranasal vaccine containing live attenuated strains of Bordetella Bronchiseptica and canine parainfluenza virus. POM-V
Further information is available from the SPC, Datasheet or package leaflet.
MSD Animal Health UK Limited. Registered office Walton Manor, Walton, Milton Keynes MK7 7AJ, UK. Registered in England & Wales no. 946942.
Advice should be sought from the medicine prescriber.
Use medicines responsibly.